Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182769-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$49.90
|
|
|
Ab182769-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$249.90
|
|
|
Ab182769-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$649.90
|
|
|
Ab182769-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,029.90
|
|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; VHH-Fc; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Letolizumab (anti-TNFSF5) - Primary antibody, specific to CD40LG, VHH-Fc |
|---|---|
| Synonyms | CD154 antibody | CD40 antigen ligand antibody | CD40L antibody | CD40LG antibody | Gp39 antibody | HIGM1 antibody | Hyper IgM syndrome antibody | IGM antibody | IMD3 antibody | Ly62 antibody | T B cell activating molecule antibody | TBAM antibody | TNF re |
| Specifications & Purity | Carrier Free, Recombinant, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | CD40LG |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, Low Endotoxin, Recombinant, Validated |
| Product Description |
Letolizumab (anti-TNFSF5) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab (anti-TNFSF5) reduces rejection, thromboembolism and prolongs the survival time. |
| Isotype | VHH-Fc |
|---|---|
| SDS-PAGE | 26.3 kDa (Light Chain) & 53.0 kDa (Heavy Chain), under reducing conditions; 205.5 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1450981-87-9 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Letolizumab (anti-TNFSF5) (Ab182769) - Flow
Flow Cytometry analysis of pLVX-puro-SYMX10-TNFSF5(CD40L)-FL-HEK293 cells labelling TNFSF5 with Letolizumab (anti-TNFSF5) (Ab182769), and negative control protein respectively, washed and then followed by PE and analyzed with the FACS EC
₅₀
is 0.05 nM.
Letolizumab (anti-TNFSF5) (Ab182769) - ELISA
Immobilized Recombinant Human CD40 Ligand protein (rp169583) at 1.0 μg/mL can bind Letolizumab (anti-TNFSF5) (Ab182769) with the EC
₅₀
of 11.26 ng/mL.
Letolizumab (anti-TNFSF5) (Ab182769) - SEC
The purity of Letolizumab (anti-TNFSF5) (Ab182769) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jul 29, 2024 | Ab182769 | |
| Certificate of Analysis | Jul 29, 2024 | Ab182769 | |
| Certificate of Analysis | Jul 29, 2024 | Ab182769 |
Starting at $59.90
Starting at $59.90
Starting at $69.90
Starting at $49.90
Starting at $119.90